203,971 Shares in Masimo Co. (NASDAQ:MASI) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 203,971 shares of the medical equipment provider's stock, valued at approximately $33,716,000. Raymond James Financial Inc. owned 0.38% of Masimo as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Jones Financial Companies Lllp acquired a new position in Masimo during the fourth quarter worth $27,000. UMB Bank n.a. increased its position in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after acquiring an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new stake in shares of Masimo during the fourth quarter valued at approximately $33,000. Blue Trust Inc. lifted its holdings in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 16.90% of the company's stock.

Masimo Price Performance

MASI traded up $0.47 on Friday, reaching $152.15. The company had a trading volume of 457,368 shares, compared to its average volume of 659,539. The business has a 50 day simple moving average of $168.04 and a 200 day simple moving average of $164.70. The company has a market cap of $8.22 billion, a price-to-earnings ratio of 104.93 and a beta of 1.28. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, sell-side analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

MASI has been the subject of several analyst reports. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Piper Sandler lifted their price objective on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Wells Fargo & Company boosted their target price on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Raymond James increased their price objective on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.